219
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Variability in CD39 and CD73 protein levels in uveal melanoma patients

, , , , , , & ORCID Icon show all
Pages 1099-1108 | Received 29 Oct 2021, Accepted 18 Jan 2022, Published online: 24 Feb 2022
 

Abstract

Extracellular adenosine is produced from ATP by CD39 and CD73, and can modulate tumor development by acting on cancer cells or immune cells. Adenosine metabolism has been poorly studied in uveal melanoma. We studied the protein levels of CD39 and CD73 in a small, well described cohort of patients with uveal melanoma. Our results show a high variability in the levels of the two proteins, both in positivity and in intensity. Our results suggest that similar studies on larger cohorts could determine the clinical value and the druggability of these enzymes in the given clinical setting.

Supplemental data for this article is available online at http://dx.doi.org/10.1080/15257770.2022.2032738

This article is part of the following collections:
19th Biennial Symposium on Purine and Pyrimidine Metabolism (PP21)

Acknowledgements

LPJ receives funding from Olav Raagholt og Gerd Meidel Raagholts stiftelse for forskning.

Conflict of interest

The authors have no conflict of interest.

Fundings

There is no particular funding for this work.

Data availability

Data is available upon request to the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.